Back to Search
Start Over
Treatment of post‐transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti‐IL6R humanised monoclonal antibody Tocilizumab.
- Source :
- British Journal of Haematology; Sep2019, Vol. 186 Issue 6, pe212-e214, 3p, 1 Chart, 1 Graph
- Publication Year :
- 2019
-
Abstract
- Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab It is characterised by brisk haemolysis of both transfused and recipient red cells, also known as "By-stander" haemolysis, with a haemoglobin (Hb) drop below pre-transfusion levels, marked increase in serum ferritin (SF) and a fall in reticulocyte count. 1 Hb, haemoglobin, LDH, lactate dehydrogenase; PTHS, post-transfusion hyperhaemolysis syndrome; RTC, reticulocytes; SF, serum ferritin. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 186
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 138456216
- Full Text :
- https://doi.org/10.1111/bjh.16103